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  Sorafenib is an oral multikinase inhibitor targeting Raf and other kinases. 
The anti-tumor effect of sorafenib is thought to be mediated through its 
inhibition of the RAS-Raf-Erk pathway, as well as its inhibition of VEGFR 
and PDGFR. Sorafenib has been effective at treating patients with renal cell 
carcinoma (RCC). Ovarian clear cell carcinoma (OCCC) is a chemoresistant 
subtype of ovarian cancer. OCCC is represented by cells with clear cytoplasm 
that resemble those observed in RCC. Using a microarray database, the gene 
expression profile of OCCC was similar to that of RCC. The effects of 
sorafenib against human OCCC are unknown. Therefore, we used sorafenib 
to treat two patients with recurrent chemoresistant OCCC, and observed 
good effect in both of them without severe side effects. We believe that 
sorafenib is an effective agent against OCCC. Given the chemoresistant 
nature of this tumor, this drug appears to be very valuable. 
 
 









Sorafenib is an oral multikinase inhibitor targeting Raf and other kinases 
(i.e., vascular endothelial growth factor receptor (VEGFR), platelet-derived 
growth factor receptor (PDGFR), Flt3, and c-KIT). The anti-tumor effect of 
sorafenib is thought to be mediated through its inhibition of the 
RAS-Raf-Erk pathway 1, which is involved in cell proliferation, as well as its 
inhibition of VEGFR and PDGFR, which play a role in angiogenesis 2, 3. 
Sorafenib has been effective at treating patients with renal cell carcinoma 
(RCC) 4 and hepatocellular carcinoma (HCC) 5.  
Ovarian clear cell carcinoma (OCCC) has a specific gene expression profile 
6, and is a chemoresistant histological subtype of ovarian cancer. OCCC is 
represented by cells with clear cytoplasm that resemble those observed in 
RCC. Using a microarray database, we previously reported that the gene 
expression profile of OCCC was similar to that of RCC, and we showed good 
effects of sorafenib in a mouse model of OCCC 7. 
  The effects of sorafenib against human OCCC are unknown. Therefore, 
we attempted to use sorafenib to treat two patients with recurrent 
chemoresistant OCCC. This is the first case report to evaluate sorafenib 
efficacy against OCCC. 
 
 Case Description 
 
  We used sorafenib monotherapy (400 mg/day, orally) in two patients with 
recurrent and chemoresistant OCCC after written informed consents were 
obtained. The efficacy of the treatment was judged based on progression-free 
survival for at least six months (RECIST 1.1). These clinical studies had been 
approved by the institutional review board (IRB) of Kyoto University in 
advanced. 
 
Clinical case 1 
A 63-year-old Japanese postmenopausal female, with 1 gestation and 0 
parturitions, who complained of dull lower abdominal pain and distension, 
visited our hospital. A 15 cm cystic tumor containing solid parts was detected 
in the lower abdomen. Total abdominal hysterectomy (TAH) with a bilateral 
salpingo-oophorectomy (BSO), pelvic/para-aortic lymphadenectomies 
(PELA/PALAs) and omentectomy were performed. After the surgery, an 
OCCC of stage Ia (PT1a, N0, M0) was diagnosed. Due to the early stage of 
the disease and her complication of IgA nephropathy, adjuvant 
chemotherapy was omitted. Thirteen months after the primary surgery, 
recurrent nodes 2 cm in diameter appeared in the ascending colon and the 
omentum. After resections of these recurrent nodes, six courses of irinotecan 
(90 mg/m2 x 2)/cisplatin (60 mg/m2) combination chemotherapy were 
administered.  
After one year, however, disseminated nodes and swelling of the lymph 
nodes were widely observed in the abdomen. Six courses of paclitaxel (175 
mg/m2)/carboplatin (AUC 6) combination chemotherapy were added. After 
six months, the recurrent peritoneal tumors had grown vigorously. 
Accordingly, the patient was administered 800 mg/day of sorafenib. The 
patient experienced a hand-foot skin reaction (grade 2, CTCAE v4.0) two 
weeks later, and subsequently, the dose was decreased to 400 mg/day, which 
was continued for six months. The sizes of the lymph nodes in the hepatic 
portal region were not significantly different before and after sorafenib 
monotherapy (Figs 1a, b). The patient’s serum levels of CA125 were 200.2 
U/ml and 181.2 U/ml before and after treatment, respectivery (Fig. 2). The 
effect of sorafenib was judged to be stable disease (progression-free survival) 
for six months. The side effects were moderate hand-foot syndrome (grade 2, 
CTCAE v4.0 ) and hypertension (160-170 mmHg, grade 2).  After sorafenib 
therapy, the tumor grew again. In spite of oral VP-16 therapy (50 mg/day), 
the tumor grew vigorously. As a result of DIC, the patient finally died 4.5 
years after the primary surgery.  
 
Clinical case 2 
A 63-year-old Japanese postmenopausal female, with 3 gestations and 3 
parturitions, who visited her neighborhood hospital due to lower abdominal 
pain, was diagnosed with an ovarian tumor. She was referred to our hospital 
and a TAH with a BSO, omentectomy, appendectomy, and sampling of the 
peritoneal nodes/right external iliac lymph nodes, were performed. The main 
tumor was demonstrated to be 10 cm in diameter, and extended widely into 
the peritoneal cavity. An OCCC of stage IIIc (PT3c, Nx, M0) was diagnosed. 
Three courses of intraperitoneal cisplatin (60mg/m2), three courses of 
intravenous irinotecan (70 mg/m2 x 2)/mitomycin (10 mg/body) chemotherapy 
and three courses of weekly paclitaxel (50 mg/m2)/carboplatin (90 mg/m2) 
combination chemotherapy were administered. The residual tumors were 
markedly reduced, and thus, optimum PELA/PALAs were performed. Six 
rounds of low-dose cyclophosphamide (230 mg/m2)/ adriamycin (20 mg/m2)/ 
cisplatin (15 mg/m2) combination chemotherapy were administered monthly.  
However, recurrence appeared in the neck lymph nodes. Neck 
lymphadenectomies were performed, and then, three courses of VP16 (60 
mg/m2)/nedaplatin (60 mg/m2) chemotherapy and irradiation (total 50 Gy) of 
the left neck were administered. For the next four years, five courses of 
monthly docetaxel (50 mg/m2) / carboplatin (200 mg/m2) chemotherapy, eight 
courses of irinotecan (60 mg/m2 x 2)/cisplatin (50 mg/m2) chemotherapy, six 
courses of gemcitabine hydrochloride (1000 mg/m2 x 2/month) and seven 
courses of nogitecan hydrochloride (0.5 mg/m2 x 5/month) were administered. 
By eight years after the primary surgery, the mediastinal, axillary and neck 
lymph nodes had increased by degrees.  
The patient then was prescribed 400 mg/day of sorafenib for five months. 
The sizes of the neck lymph nodes were not significantly different before and 
after treatment (Figs 3a, b), which was judged to indicate ‘stable disease’ for 
six months. The serum levels of CA125 were 193.2 U/ml and 203.5 U/ml 
before and after the treatment, respectively (Fig. 4). The only side effect was 
mild hand-foot syndrome (grade1).  
After sorafenib therapy, the metastatic neck lymph nodes increased 
suddenly. External irradiation against the bilateral neck regions (60 Gy), the 
right axillary lymph nodes (28 Gy) and the para-aortic lymph nodes (30 Gy) 
was performed. However, airway narrowing occurred due to swelling of the 
neck lymph nodes. After a tracheotomy, the patient died due to ileus and 
bleeding from the bronchi. This was approximately nine years after the 
primary surgery. 
 
                        Discussion 
 
 Epithelial ovarian carcinoma is histologically divided into serous (OS), 
endometrioid (OE), mucinous (OM) and OCCC subtypes. OM and OCCC are 
both commonly considered to be chemoresistant tumors. OCCCs are rare 
tumors in Europe and the United States 8 ; however, they occur often in 
Japan (20%) 9. Therefore, we have searched for agents that are effective 
against OCCC.  
We previously showed that the gene expression profile of OCCC was 
similar to that of RCC using microarray datasets of ovarian cancer cell lines 
and human cancer tissues specimens 7. We also showed the genes 
exclusively expressed in OCCC, termed OCCC signature, contained a large 
gene network consisting of 66 genes, including hepatocyte nuclear factor 
1-beta (HNF1B) and hypoxia inducible factor 1-alpha subunit (HIF1A) 6. 
HNF1B is functionally associated with renal morphogenesis 10. In addition, 
pathway analysis indicated the Ras-Raf-Erk signaling is activated in OCCC 
7. 
  RCC is also a chemoresistant tumor. Sorafenib has recently been 
approved for RCC, and is considered to be a reasonable molecular targeting 
drug against RCC. All sporadic and inherited forms of RCC are associated 
with mutations in the VHL gene and loss of heterozygosity 11, 12, resulting in 
the stabilization of the HIF1A protein. HIF1A activates multiple growth 
factor receptors, such as the EGFR, PDGFR and VEGFR. In addition, 
increased Ras pathway signaling is observed in RCC 13. The anti-tumor 
effect of sorafenib is thought to be mediated through its inhibition of the 
RAS-Raf-Erk pathway as well as its inhibition of VEGFR and PDGFR 1-3. 
We showed that orally administered sorafenib significantly inhibited the 
growth of RMG-2, a representative OCCC cell line, in nude mice 7. We 
therefore attempted to use sorafenib for human patients with recurrent 
chemoresistant OCCC. 
Both of our patients with OCCC were judged to have ‘stable disease’ 
following the use of sorafenib monotherapy and exhibited progression-free 
survival of at least six months. This suggests that sorafenib is an effective 
agent against recurrent OCCC. Our two patients were able to continue 
sorafenib monotherapy (400 mg/day) without severe side effects. Both 
patients had mild/moderate hand-foot syndrome (grades 1 and 2) and one 
also had hypertension (grade 2). In fact, we used sorafenib monotherapy for 
another patient with OCCC for two months. However, therapy had to be 
stopped due to Trousseau syndrome. The disease was stable for two months, 
and the side effect was a mild rash (grade 1). 
Recently, the Gynecologic Oncology Group reported that sorafenib had 
modest antitumor activity, but did not provide a sufficient effect as a 
treatment for ovarian cancer 14. Fifty-nine patients with measurable 
diseases of recurrent ovarian or peritoneal carcinoma were enrolled in this 
study, but only 14 patients (24%) survived progression-free for six months. 
This study was conducted mostly for the OS subtype (90%) ，whereas only 
one patient (1.4%) had OCCC. Interestingly, in this study, one of the two 
patients with partial responses was the patient with OCCC. The data from 
this study appear to support our result suggesting promising effects of 
sorafenib against OCCC.  
The conventional dose of sorafenib is 800 mg/day14,15. For case 1, we 
initiated sorafenib treatment with a dose of 800 mg/day, but the dose was 
soon decreased to 400 mg/day due to hand-foot skin reaction. In a clinical 
trial conducted for Japanese patients with RCC, dose reduction or therapy 
interruption due to adverse events was required for as many as 81% of the 
patients, which is a much higher percentage than for American or European 
patients 16. We therefore initiated treatment with a dose of 400 mg/day for 
case 2. Regardless of the decreased dose, sorafenib showed significant 
anti-tumor activity in the two OCCC patients. 
We believe that sorafenib is an effective agent against OCCC. Given the 
chemoresistant nature of this tumor, this drug appears to be very valuable. 
A clinical trial should be performed using sorafenib to treat OCCC. In 
addition, a further combination regimen17 using sorafenib may be more 
effective against OCCC. 
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Figure 1a & Figure 1b :  
 The sizes of the lymph nodes in the hepatic portal region were 19.1 mm 
and 19.5 mm (-30%~+20%; shortest diameter rule, RECIST 1.1), which 
were not significantly different before (1a) and after (1b) sorafenib 
monotherapy. 
 
Figure 2 :  
Clinical course of the patient and changes in CA125 (case1). 
 Sorafenib monotherapy suppressed CA125 elevation. 
 
Figure 3a & Figure 3b : 
The size of the left neck lymph node was not significantly different before 
(3a) and after (3b) treatment (14.3, 10.3 mm vs. 14.3, 10.8 mm, respectively 
(-30%~+20%; shortest diameter rule, RECIST 1.1)).     
 
Figure 4 :  
Clinical course of the patient and changes of CA125 (case 2) 
Sorafenib monotherapy decreased CA125 level temporarily. 
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